Antidote, formerly known as TrialReach, is a digital health company that works with a network of more than 300 partners such as patient advocacy groups to reach potential participants in clinical trials and offers pre-screening and referral management support.
OneStudyTeam provides a cloud-based platform, StudyTeam, that biopharma sponsors including Amgen, AstraZeneca, and Eli Lilly use to view pre-screening and enrollment data. Ralph Passarella, the CEO of OneStudyTeam, explained how the two systems complement each other.
“Where OneStudyTeam provides visibility to measure and understand gaps in enrollment strategy, Antidote has mastered identifying those critical patients and matching them to the right trial. This collaboration spans the recruitment and enrollment continuum to drive diversity, equity, inclusion, and representation among trial candidates,” said Passarella.
Through the partnership, OneStudyTeam has integrated Antidote into its referral partner interface. The integration is intended to streamline site workflows and deliver referrals and patient demographic information directly into the StudyTeam platform.
For sites, the integration could mean higher quality referrals in their StudyTeam enrollment management platform, while sponsors may receive more actionable enrollment data, including recruitment source traceability.
The partners framed the collaboration as supportive of efforts to increase the diversity of clinical trials, a task that OneStudyTeam has recently tried to address through its race and ethnicity feature. By working together, the collaborators envision Antidote receiving “more granular funnel insights” that help it to recruit the right patients while OneStudyTeam works with sites to retain the participants.
“Research is only as good as who participates, which is why Antidote is dedicated to leading the way for a more diverse research landscape,” said Laurent Schockmel, CEO of Antidote. “OneStudyTeam shares this aspect of our mission, and it’s an honor to offer our clients a solution to drive diversity, equity, and inclusion in clinical trials.”